This is a Phase 2b clinical study, multicenter, randomized, open-label, assessor-blinded, superiority study. The study will compare dalbavancin to standard of care antibiotic therapy for the completion of therapy in patients with complicated…
- Investigator
- Kartik Cherabuddi
- Status
- Accepting Candidates
- Ages
- 18 Years - 99 Years
- Sexes
- All